[ARNA] Arena Pharmaceuticals, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 396.16 M

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 1.53 Change: 0.06 (4.08%)
Ext. hours: Change: 0 (0%)

chart ARNA

Refresh chart

Strongest Trends Summary For ARNA

ARNA is in the long-term up 136% in 4 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Arena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel drugs that target G protein-coupled receptors. The company offers BELVIQ, a drug used to treat chronic weight management in adults. Its products under development include APD811, an agonist of the prostacyclin receptor, which has completed single- and multiple-ascending dose Phase I trials for the treatment of pulmonary arterial hypertension; and temanogrel, an inverse agonist of the serotonin 2A receptor for the treatment of thrombotic diseases, which has completed single- and multiple-ascending dose Phase I trials. The company?s products under development also comprise APD334, an agonist of the sphingosine 1-phosphate subtype 1 receptor for the treatment of conditions related to autoimmune diseases, which has completed Phase I single-ascending dose trial; and APD371, an agonist of the cannabinoid receptor 2 that is in Phase I single-ascending dose trial for the treatment of pain. It also manufactures drug

Fundamental Ratios
Shares Outstanding243.04 M EPS0.02 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -4.26% Sales Growth - Q/Q33.35% P/E65.5
P/E To EPS Growth P/S9.34 P/BV3.07 Price/Cash Per Share
Price/Free Cash Flow-3.59 ROA-16.44% ROE-46.18% ROI
Current Ratio3.61 Quick Ratio3.46 Long Term Debt/Equity0.35 Debt Ratio0.58
Gross Margin76.36% Operating Margin-243.99% Net Profit Margin-140.4% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities101.41 M Cash From Investing Activities-1.07 M Cash From Operating Activities-23.02 M Gross Profit8.66 M
Net Profit-24.3 M Operating Profit-21.74 M Total Assets362.29 M Total Current Assets268.62 M
Total Current Liabilities74.36 M Total Debt70.17 M Total Liabilities233.35 M Total Revenue12.26 M
Technical Data
High 52 week49.63 Low 52 week30.89 Last close43.58 Last change-0.37%
RSI72.62 Average true range2.02 Beta1.02 Volume2.08 M
Simple moving average 20 days7.91% Simple moving average 50 days9.66% Simple moving average 200 days6.16%
Performance Data
Performance Week-0.91% Performance Month6.06% Performance Quart10.83% Performance Half-2.22%
Performance Year28.63% Performance Year-to-date11.89% Volatility daily3.16% Volatility weekly7.07%
Volatility monthly14.48% Volatility yearly50.18% Relative Volume420.94% Average Volume624.51 K
New High New Low

News

2019-11-14 09:00:00 | Everest Medicines Achieved First Patient Dosing Milestone in Etrasimod Phase 3 Clinical Study in Ulcerative Colitis Patients in Asia

2019-11-10 07:43:07 | Can You Imagine How Chuffed Arena Pharmaceuticals's NASDAQ:ARNA Shareholders Feel About Its 189% Share Price Gain?

2019-11-08 17:15:32 | Edited Transcript of ARNA earnings conference call or presentation 7-Nov-19 9:30pm GMT

2019-11-08 08:56:01 | Arena Pharmaceuticals' ARNA Q3 Loss Widens, Revenues Beat

2019-11-07 16:01:00 | Arena Reports Third Quarter Financial Results with Continued Progress on Clinical Programs

2019-11-06 08:30:00 | Arena Pharmaceuticals Presented New Data Highlighting the Human Mass Balance and Metabolism Profile of Etrasimod at AAPS

2019-11-05 17:41:00 | Arena Pharmaceuticals to Present at Upcoming Investor Conferences

2019-10-31 11:45:03 | United Therapeutics UTHR Q3 Earnings & Sales Top, Stock Up

2019-10-31 08:30:00 | Arena Pharmaceuticals to Release Third Quarter 2019 Financial Results and Provide Corporate Update on November 7

2019-10-28 08:30:00 | Arena Pharmaceuticals Announces First Subject Dosed in ADVISE Phase 2 Trial Evaluating Etrasimod in Atopic Dermatitis

2019-10-23 13:26:35 | Hedge Funds Have Never Been This Bullish On Arena Pharmaceuticals, Inc. ARNA

2019-10-22 16:01:00 | Arena Pharmaceuticals Presented New Data Analyses Demonstrating the Long-Term Safety and Efficacy of Once-Daily Etrasimod in Patients with Moderately to Severely Active Ulcerative Colitis at UEG Week

2019-10-18 03:01:00 | Arena Pharmaceuticals' Presence at United European Gastroenterology Week Bolsters Commitment to the Gastrointestinal Disease Community

2019-10-05 09:51:50 | What Kind Of Shareholder Owns Most Arena Pharmaceuticals, Inc. NASDAQ:ARNA Stock?

2019-09-26 08:30:00 | Arena Pharmaceuticals Presented New Data from the Phase 2 OASIS trial for Etrasimod at the World Congress of Gastroenterology Meeting

2019-09-25 08:30:00 | Arena Pharmaceuticals to Present at the Cantor Global Healthcare Conference on October 2

2019-09-17 08:30:00 | Arena Pharmaceuticals to Present New Preclinical Atopic Dermatitis Data for Etrasimod at the European Society for Dermatologic Research Annual Meeting

2019-09-12 11:25:03 | United Therapeutics' Trevyent NDA for PAH Accepted by FDA

2019-09-10 23:15:04 | Arena Pharmaceuticals Inc ARNA EVP, General Counsel & Sec Steven W Spector Sold $2. ...

2019-09-09 08:30:00 | Arena Pharmaceuticals Presented New Patient-Reported Outcomes Data for Olorinab at the European Society of Neurogastroenterology & Motility NeuroGASTRO 2019 Meeting

2019-09-05 11:23:54 | Does Arena Pharmaceuticals, Inc.'s NASDAQ:ARNA CEO Salary Compare Well With Others?

2019-08-28 08:30:00 | Arena Pharmaceuticals to Participate in Upcoming Investor Conferences

2019-08-13 12:49:14 | 25 Biggest Marijuana Companies in the World

2019-08-08 16:47:20 | Edited Transcript of ARNA earnings conference call or presentation 7-Aug-19 8:30pm GMT

2019-08-08 16:08:47 | This Biotech Crashed On 'Erroneous' Report — Plus 2 Stocks That Diverged

2019-08-08 10:34:02 | Arena Pharmaceuticals' ARNA Q2 Loss Widens, Revenues Meet

2019-08-08 04:23:53 | Arena Pharmaceuticals Inc ARNA Q2 2019 Earnings Call Transcript

2019-08-07 16:01:00 | Arena Reports Second Quarter Financial Results with Strong Liquidity Position, and Initiation of Etrasimod ELEVATE UC 52 and Olorinab CAPTIVATE Trials

2019-08-06 15:50:19 | Is Arena Pharmaceuticals, Inc. NASDAQ:ARNA A High Quality Stock To Own?

2019-08-01 09:49:01 | United Therapeutics UTHR Q2 Earnings & Sales Beat, Down Y/Y

2019-07-31 08:30:00 | Arena Pharmaceuticals to Release Second Quarter 2019 Financial Results and Provide Corporate Update on August 7

2019-07-29 10:34:02 | Analysts Estimate Arena Pharmaceuticals ARNA to Report a Decline in Earnings: What to Look Out for

2019-07-25 09:00:01 | Arena Pharmaceuticals ARNA Upgraded to Buy: Here's Why

2019-07-25 08:30:00 | Arena Pharmaceuticals Announces First Subject Dosed in CAPTIVATE Phase 2 Trial Evaluating Olorinab in Abdominal Pain Associated with Irritable Bowel Syndrome

2019-07-09 13:32:21 | Should Arena Pharmaceuticals, Inc. NASDAQ:ARNA Be Your Next Stock Pick?

2019-06-18 12:30:04 | A Company's First Profit Can Mean Big Profits for Investors

2019-06-18 10:38:02 | Arena Initiates Dosing in Pivotal Colitis Study on Etrasimod

2019-06-17 08:30:00 | Arena Pharmaceuticals Announces First Subject Dosed in ELEVATE UC 52 Global Phase 3 Trial Evaluating Etrasimod in Ulcerative Colitis

2019-06-14 18:29:41 | Did Hedge Funds Drop The Ball On Arena Pharmaceuticals, Inc. ARNA

2019-06-13 08:30:00 | Arena Pharmaceuticals to Present at JMP Securities Life Sciences Conference on June 19

2019-06-07 09:30:01 | Why Is Arena Pharmaceuticals ARNA Up 9.1% Since Last Earnings Report?

2019-06-06 12:32:35 | Does Market Volatility Impact Arena Pharmaceuticals, Inc.'s NASDAQ:ARNA Share Price?

2019-05-21 07:30:00 | Corvidia Therapeutics Announces Dr. Preston Klassen Joins its Board of Directors

2019-05-17 08:30:00 | Arena Pharmaceuticals' Presence at Digestive Disease Week DDW Reinforces Commitment to the Gastrointestinal Disease Community

2019-05-13 11:35:18 | Cannabis Sector Weekly Update: Sell-Off amid Market Weakness

2019-05-13 09:00:01 | All You Need to Know About Arena Pharmaceuticals ARNA Rating Upgrade to Buy

2019-05-13 08:30:00 | Arena Pharmaceuticals to Participate in Upcoming Investor Conferences

2019-05-10 19:45:04 | Arena Pharmaceuticals Inc ARNA Q1 2019 Earnings Call Transcript

2019-05-10 07:04:25 | Did Business Growth Power Arena Pharmaceuticals's NASDAQ:ARNA Share Price Gain of 226%?

2019-05-09 16:24:00 | S&P 500, Nasdaq end lower for fourth day after Trump claims China ‘broke the deal’